Search results
Found 34 matches for
We are looking for healthy adults to take part in the initial trial of a potential new vaccine against a virus considered to be a crucial missing element in the childhood vaccination programme. **Please note, this study has recruited a sufficient number of participants**
First Volunteer Receives Lassa Fever Vaccine in Cutting-edge Oxford Trial
4 December 2025
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus. The trial, conducted by the Oxford Vaccine Group, and funded by the Coalition for Epidemic Preparedness Innovations (CEPI), will assess the safety and immune response of the ChAdOx1 Lassa vaccine. 31 people aged 18-55 will participate in the trial in total.
Oxford-led study shows vaccine protection against Salmonella Paratyphi A
30 October 2025
Results from a study published today in The New England Journal of Medicine show that a vaccine can protect people against Salmonella Paratyphi A infection.
Major investment puts UK universities at the forefront of groundbreaking lymph node research
14 October 2025
Three UK universities have been granted over £1.7m by the Medical Research Council (MRC) to establish a network of lymph node research centres across the UK. The novel LEGACY IIII Network (Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation) will be co-led by the Universities of Oxford, Cardiff and Newcastle and will establish ten specialist lymph node research centres across the country.
New jab protects babies from serious lung infection, study shows
23 July 2025
Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.
Oxford vaccine against deadly Nipah virus granted EMA PRIME designation for the first time
9 June 2025
The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.
New MenB Vaccine Shows Promise in Early-Stage Trial Results
19 May 2025
The outcome of a trial published in Science Translational Medicine, shows encouraging results for a new vaccine targeting group B meningococcus (MenB), a significant cause of meningococcal disease worldwide, and establishes proof-of-concept in humans that a gene-based vaccine platform can induce protective antibody responses against bacteria.
Trial results for first vaccine against blood-stage malaria show it is well-tolerated and offers effective protection
10 December 2024
Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease – the first inoculation to do so.
Typhoid vaccine trial confirms sustained protection for older children
10 October 2024
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
New research identifies autoimmunity against a key anti-inflammatory regulator in inflammatory bowel disease
- Clinical Trials
- Department
- Gastroenterology
- Immunology
- Publication
- Research
- Research Methods
- University
4 August 2024
A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.
New trial launches for two-in-one vaccine to prevent RSV and hMPV
12 July 2024
Scientists at the University of Oxford have launched a phase 1 study to test two investigational mRNA vaccines: one for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and a second for RSV alone in infants aged five to eight months old. The vaccines are being developed by Moderna.
Ground-breaking study reveals how COVID-19 vaccines prevent severe disease
3 May 2024
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
New trial to study how the human immune system adapts to ‘tolerate’ malaria parasites
18 March 2024
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.
Student wins award for Individual Excellence in Clinical Data Management
7 March 2024
Yama Mujadidi, DPhil student and Clinical Trials IT & Development Lead at the Oxford Vaccine Group, has been awarded the prize for Individual Excellence by the Association for Clinical Data Management.
MDUK Oxford Neuromuscular Centre celebrates five year anniversary
31 January 2024
The Department of Paediatrics at the University of Oxford is celebrating the five-year anniversary of a partnership with MDUK. Founded in January 2019, the MDUK Oxford Neuromuscular Centre was set up to drive the development of new therapies and treatments and increase the capacity of clinical trials for muscle wasting and weakening conditions in the UK.
First in-human vaccine trial for Nipah virus
11 January 2024
The University of Oxford has launched a new clinical trial to test a vaccine against the deadly Nipah virus.
New campaign by Oxford Vaccine Group hopes to boost jab numbers
8 December 2023
Experts have launched a new campaign in a bid to boost waning vaccine uptake by giving people more information about how clinical trials work. Researchers hope to alleviate hesitancy by showing with a simple animation and comic the complex way vaccines are developed.
Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines
25 October 2023
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
First vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)
18 September 2023
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).
First in-human trials commence for CCHF vaccine
12 September 2023
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.